Momentum Continuation
Liquid US stocks in the top 7% of relative strength (above the 93rd percentile), trading above the 50-day moving average and moving enough each day to be worth a swing trade.
MarketSurge alternative
QM Screener runs six published momentum and trend methodologies across the full US market every trading-day close. A focused, lower-priced alternative to MarketSurge (formerly MarketSmith) for traders who want methodology-driven screens without the IBD subscription.
A high-level comparison. Both tools serve momentum-focused US-equity traders; the difference is in scope, workflow, and price.
| QM Screener | MarketSurge | |
|---|---|---|
| Primary focus | Six published momentum/trend screens | IBD methodology platform (CAN SLIM, RS Rating, IBD lists) |
| Methodologies baked in | momentum continuation, trend template, VCP, EP, gappers, swing | CAN SLIM, RS Rating, proprietary IBD scoring |
| Charting & fundamentals | Built-in candlestick charts with EMA/SMA overlays; no fundamentals — TradingView export for more | Built-in charts and IBD fundamentals |
| Refresh cadence | Daily after the US close | Daily / intraday |
| TradingView export | Yes — one-click watchlist | Proprietary |
| Pricing tier | Free plan · $10 / month · $84 / year | Premium subscription |
QM Screener runs six well-known momentum strategies against the full US equity market every trading day, then surfaces the names that pass each strategy's filters in one dashboard.
It's built for traders who want a daily watchlist generator without rebuilding scans by hand. Every passing ticker is shown alongside the actual values that satisfied the filter, so results are auditable rather than opaque.
Liquid US stocks in the top 7% of relative strength (above the 93rd percentile), trading above the 50-day moving average and moving enough each day to be worth a swing trade.
A published eight-point trend checklist. Price is above the 50-, 150- and 200-day simple moving averages (SMA), the averages are stacked 50 over 150 over 200, the 200-day is rising, price is within 25% of its 52-week high and at least 30% above its 52-week low, and the RS rank is 70 or better.
The price range tightens from 30 days to 15 to 5 while volume dries up, with price above the 50-day moving average.
Stocks that opened at least 4% above the prior close on at least twice their 50-day average volume, while already above the 50-day moving average.
Liquid stocks above both the 50-day and 200-day moving averages, with an RS rank of 70 or better and an average daily range between 3% and 8%.
Staples, healthcare and utility stocks above the 200-day moving average that swing less than the market (one-year beta against SPY under 1.0).
Start with a 7-day free trial. Cancel anytime.
Monthly
$10 / month
Billed monthly after a 7-day free trial.
Annual
$84 / year
$7/month, billed yearly. 7-day free trial.
For traders whose main use of MarketSurge is the screening workflow — particularly trend-template screens and momentum leaders — QM Screener is a focused, lower-priced option. QM Screener does not replicate IBD's proprietary RS Rating or IBD curated lists; if those are central to your workflow, MarketSurge is the better fit.
No. QM Screener uses standard momentum and trend metrics (returns, ADR, moving averages, breakout patterns) drawn from published momentum, trend, and VCP methodologies, not IBD's proprietary scoring.
It is one of the six screens. The standard 8-point trend template is applied across the full US equity universe daily, and each passing ticker shows the actual price, moving-average, and 52-week-high values that satisfied the filter.
QM Screener has a free plan — the top 5 names in each of the six screens, no card. Paid is $10 per month or $84 per year after a 7-day free trial. MarketSurge's subscription is materially more expensive.
MarketSurge, MarketSmith, IBD, CAN SLIM, and Relative Strength Rating are trademarks of their respective owners. QM Screener is an independent product and is not affiliated with or endorsed by Investor's Business Daily.